Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:
The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| genetic landscape of PCD | number and percentage of genetic landscape of FISH and NGS in patients with Plasma Cell Disorders | 18 months in 498 patients |
| Measure | Description | Time Frame |
|---|---|---|
| genetic correlation | genetic landscape correlation between FISH and NGS in MM patients | 18 months in MM patients |
| genetic landscape of relapse MM patients | number of genetic landscape in relapse MM patients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis who were performed FISH and/or NGS testing
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chutima Kunacheewa | Contact | 66896790959 | chutima.kua@mahidol.ac.th | |
| Weerapat Owattanapanich | Contact | 66891081983 | weerapat.owa@mahidol.ac.th |
Not provided
Not provided
Need a consensus from colleagues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 18 months in MM patients |
| overall survival | time of survival in MM patients | 18 months |
| progression free survival | time of disease progression in MM patients | 18 months |
| factor of genetic landscape differentiation | number of MM patients who have the different factors such as gender, age, and comorbidities. | 18 months in MM patients |
| gender | number and percentage of male and female | 18 months in 498 patients |
| age | age in years | 18 months in 498 patients |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided